中文ENGLISH
分享到 

About Haisco

HOME > About Haisco > Group Profile

关于海思科

关于海思科

Haisco Pharmaceutical Group

 

•Haisco Pharmaceutical Corporation:
Haisco pharmaceutical Corporation (Haisco Pharmaceuticals), founded in 2000, is a public listed company focusing on R & D of therapeutic new drugs. Meanwhile Haisco Pharmaceuticals has outstanding capability of marketing and sales. Listed on Shenzhen Stock Exchange on Jan. 2012 (Haisco, Stock exchange code 002653), Haisco Pharmaceuticals ranks No.3 in chemical pharmaceutical industry of China. With over 900 agencies which have more than 8000 sales representatives from 1500 cities, products of Haisco Pharmaceuticals are sold to more than 3000 hospitals all over the China. The annual terminal sales is over US$800 million.
 
•Employees
Haisco Pharmaceuticals currently has 1770 employees, including over 50 PhDs and 100 masters.
 
•Subsidiaries
The group company has seven subsidiary companies, including Xizang Haisco Pharmaceutical Group Co., Ltd, Hong Kong Haisco Pharmaceutical Co., Ltd, Sichuan Haisco Pharmaceutical Co., Ltd, Liaoning Haisco Pharmaceutical Co., Ltd, Huludao Xintianweng Pharmaceutical Co., Ltd, Chengdu Kangxin medical development Co., Ltd, Xizang Haisco biological technology co., Ltd.
 
•Market position
Haisco Pharmaceuticals is the leader company in the market segment of parenteral nutrition of China. As top ranking company in manufacture and sales of drugs for liver disease, Haisco is an important player in the market segments of liver and digestive disease.
 
• Exchange Sock
Current market value is US$4.5billion; Exchange value in 2013 was US$2.8 billion.
 
•Industry position:
Haisco Pharmaceuticals is ranked top 3 among all listed chemical and chemistry drug manufacturer companies according to market value. It is also listed No.3 in the Forbes Top 100 Most Potential Chinese Listed Enterprises Year of 2014; No.1 in the group of medical and pharmaceutical enterprises.
 
Marketing and Sales:
Haisco’s 2013 total revenues was US$192 million and net income was US$72 million. The net profit growth rate was over 37%. The prospect total revenues will be US$256 millions in 2015.
Haisco Pharmaceuticals manages over 900 agencies in China, using sales model of Regional Sales Agent. The agencies have more than 8000 sales representatives from 1500 cities, among which 110 are big cities with population over one million. More than 3000 hospitals rank 2 or higher in China are covered by Haisco Pharmaceuticals’ sales network.
 
• Products
The 4 major products of Haisco are all the first generics in China, which have been included in the National Health Insurance Catalog. Our products have high reputation and are widely accepted by doctors and patients. The products are being used in 80% first rank hospitals in China.